JOINTOWN PHARMACEUTICAL GROUP CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.21 CNY | 0.00% |
|
-3.86% | +17.12% |
| Sales 2024 * | 174B 23.99B 1,921B | Sales 2025 * | 192B 26.55B 2,126B | Capitalization | 31.26B 4.31B 345B |
|---|---|---|---|---|---|
| Net income 2024 * | 2.81B 388M 31.04B | Net income 2025 * | 3.35B 462M 37B | EV / Sales 2024 * | 0.23 x |
| Net Debt 2024 * | 9.24B 1.28B 102B | Net Debt 2025 * | 12.56B 1.73B 139B | EV / Sales 2025 * | 0.23 x |
| P/E ratio 2024 * |
11.4
x | P/E ratio 2025 * |
9.59
x | Employees | 30,141 |
| Yield 2024 * |
4.06% | Yield 2025 * |
4.61% | Free-Float | 40.28% |
More Fundamentals
* Assessed data
More news
| 1 week | -3.86% | ||
| Current month | +1.86% | ||
| 1 month | +5.94% | ||
| 3 months | +14.66% | ||
| 6 months | +10.35% | ||
| Current year | +17.12% |
1 week
8.00
8.60
1 month
7.868.62
Current year
6.528.95
1 year
6.508.95
3 years
5.128.95
5 years
5.129.87
10 years
5.1216.87
| Managers | Title | Age | Since |
|---|---|---|---|
Wei He
CEO | Chief Executive Officer | 38 | 30/09/21 |
Chang Yun Liu
CHM | Chairman | 42 | 31/07/17 |
Ying Zheng Xu
CHM | Chairman | 51 | 31/08/14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gu Liang Tang
BRD | Director/Board Member | 62 | 04/11/20 |
Bao Lin Liu
FOU | Founder | 71 | 28/02/99 |
Zhao Nian Liu
BRD | Director/Board Member | 64 | 15/11/08 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.42% | 2 M€ | -16.59% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 8.21 | 0.00% | 20,114,730 |
| 25/04/24 | 8.21 | -0.24% | 12,958,290 |
| 24/04/24 | 8.23 | +0.37% | 22,266,020 |
| 23/04/24 | 8.2 | -3.53% | 19,586,370 |
| 22/04/24 | 8.5 | -0.47% | 14,941,630 |
End-of-day quote Shanghai S.E., April 25, 2024
More quotes
Jointown Pharmaceutical Group Co., Ltd. is principally engaged in the wholesaling and retailing of pharmaceuticals and medical equipments. The Company is also engaged in the research, development and production of drugs, as well as the provision of relevant value-added services. The Companyâs products mainly include western medicines, proprietary Chinese medicines, Chinese medicine pieces, Chinese herbal medicines, medical equipments, health care products, cosmetics, among others. The Company mainly provides services to direct sales or franchise stores through its retailing businesses.
Sector
Pharmaceuticals
Calendar
26/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
8.21
CNY
Average target price
10.18
CNY
Spread / Average Target
+24.06%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +17.12% | 4.31B | |
| +17.35% | 71.39B | |
| +2.39% | 25.1B | |
| +5.38% | 8.59B | |
| +6.69% | 8.19B | |
| -20.96% | 7.91B | |
| +0.49% | 4.54B | |
| -2.61% | 3.86B | |
| +22.08% | 3.64B | |
| +7.96% | 3.29B |
- Stock Market
- Equities
- 600998 Stock
